奥地利科学研究院医学实验胚胎学博士后职位

We are looking for an enthusiastic postdoc who would like to pursue experimental and/or bioinformatic research on the role of epigenetics in stem cells, cancer, and other diseases. Our lab is based at the CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences in Vienna. It combines advanced technology (single-cell sequencing, drug screening, mass spectrometry, machine learning, etc.) with relevant biological models and access to patients, with the goal of developing epigenetics-based therapies.

The Candidate
We are looking for highly motivated and academically outstanding candidates who want to pursue a scientific career in the emerging field of medical epigenomics. An ideal candidate would have a background in molecular biology (including functional genomics, chemical biology, human genetics, molecular medicine, etc.) or in the computational sciences (bioinformatics, physics, engineering, etc.) and a strong interest in working together with collaborators in the entire spectrum of epigenetics, medical genomics, and bioinformatics.

The Lab [">http://www.medical-epigenomics.org/]*
The Medical Epigenomics Lab at CeMM combines large-scale epigenome analysis with stem cell biology and computational modeling, in order to better understand and treat cancer and other diseases. We focus broadly on the blood as the organ that connects all other organs, and we work closely with biologists and medical researchers at the Medical University of Vienna, aiming to advance personalized medicine through epigenome sequencing and bioinformatic innovation. Specific research interests include (but are not limited to):
• Epigenomics. We perform large-scale epigenome mapping in order to dissect the dynamics of cancer development and emerging drug resistance. This work is closely connected with the BLUEPRINT project and the International Human Epigenome Consortium.
• Technology. Exciting biomedical research is often driven by new technologies. Our lab is therefore heavily invested into technology development, including single-cell protocols, nanopore sequencing, CRISPR, and epigenome editing.
• Bioinformatics. New algorithms and advanced computational methods allow us to accurately infer epigenetic cell states from large-scale datasets, in order to reconstruct the epigenetic landscape that controls cellular differentiation and reprogramming.
• Diagnostics. Using large-scale DNA methylation mapping, bioinformatic prioritization, and functional characterization, we strive to develop clinically relevant biomarkers for informing personalized cancer therapy.

The Project
The lab is driven by the ideas of all its members. If you already have a project in mind, we would like to hear from you. If not, here are a few topics for inspiration: (i) Why is leukemia a disease of the elderly? Can we identify an “epigenetic clock” that counts down toward leukemia? What is wrong with this clock in those rare cases of childhood leukemia? (ii) Can we construct a blood cancer from scratch, by inducing only epigenetic defects? Which combination of pathways provides the minimum core of an epigenetic leukemia? (iii) How can we make epigenome data useful for personalized medicine? Every physician uses Google – can we build a “Google for the epigenome”?

The Principal Investigator [">http://christoph-bock.org/]*
Christoph Bock is an epigenome researcher and principal investigator at the CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences. He is also a guest professor at the Medical University of Vienna's Department for Laboratory Medicine, the scientific coordinator of the Bio-medical Sequencing Facility at CeMM, and an adjunct group leader at the Max Planck Institute for Informatics in Germany. He has a background in bioinformatics and epigenomics (http://scholar.google.com/citations?user=9qSsTcIAAAAJ), with a PhD at the Max Planck Institute for Informatics (for which he received an Otto Hahn Medal by the Max Planck Society) and postdoctoral re-search at the Broad Institute and Harvard University (where he contributed to the Roadmap Epigenomics Project). Christoph joined CeMM in 2012, and he was a 2014 recipient of the New Frontier Group award of the Austrian Academy of Sciences. He leads Genom Austria (http://www.personalgenomes.org/austria), which is the Austrian Personal Genome Project; and he is a principal investigator in several EU projects, most notably for BLUEPRINT, which is the European contribution to the International Human Epigenome Consortium.

The Institute [">http://www.cemm.at/]*
The CeMM Research Center for Molecular Medicine is an international and interdisciplinary research institute of the Austrian Academy of Sciences. Driven by medical needs, CeMM integrates basic research and medical expertise to pursue innovative diagnostic and therapeutic approaches focused on cancer, inflammation, and immune disorders. CeMM is located in a new building at the center of Vienna’s Medical University campus, within walking distance of Vienna’s historical city center. According to a study by “The Scientist”, CeMM is among the top-5 best places to work in academia world-wide (http://the-scientist.com/2012/08/01/best-places-to-work-academia-2012). Vienna is frequently ranked the world’s best city to live. It is a United Nations city with a large English-speaking community. The official language at CeMM is English, and more than 30 different nationalities are represented at the institute.